Molecular Markers of Prognosis in Myelodysplastic Syndromes--Review.
10.7534/j.issn.1009-2137.2016.01.055
- Author:
Yuan-Yuan XU
1
;
Li YU
2
Author Information
1. Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.
2. Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China. E-mail: chunhuiliyu@yahoo.com.
- Publication Type:Journal Article
- MeSH:
Biomarkers;
Humans;
Mutation;
Myelodysplastic Syndromes;
diagnosis;
genetics;
Prognosis
- From:
Journal of Experimental Hematology
2016;24(1):285-289
- CountryChina
- Language:Chinese
-
Abstract:
Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic disorders, which have a wide range of clinical manifestations and eventual outcomes. It is useful to predict its risk for patients prognosis. The International Prognostic Scoring System (IPSS) has been the standard tool used to stratify MDS patients since 1997. Other models have been created to improve upon the IPSS.With the application of next-generation sequencing (NGS), several research groups found mutated genes in the majority of MDS patients. Recently, more and more results prove that these mutations have independent prognostic significance. However, mutational information is complex and there are challenges for its clinical application. Despite these limitations, NGS can refine the prediction of prognosis for MDS patients and will improve the care of them. In this article the curent prognostic markers of MDS, the mdecular biological events as new prognostic markers and their advaintages and drawbacks are summarized.
